Market Overview

Benzinga's Top Initiations

Related ALXN
UPDATE: 8-K from Alexion Pharma Shows FDA Issued Form 483 at Aug. Inspection of Site, Does Not Expect Material Financial Effect Related to FDA Concern
Alexion Initiates Multinational Registration Trial of Eculizumab for Prevention of DGF after Kidney Transplantation
Related DHR
Events for the Week of Sept. 15-19th
US Stock Futures Down Ahead Of Industrial Production Report

Analysts at Citigroup initiated coverage on shares of Alexion Pharmaceuticals (NASDAQ: ALXN) with a “neutral” rating. Alexion's shares closed at $93.59 yesterday. Alexion's trailing-twelve-month operating margin is 35.20%.

BMO Capital initiated coverage on shares of Danaher (NYSE: DHR) with an “outperform” rating. Danaher's shares closed at $53.07 yesterday. Danaher's trailing-twelve-month revenue is $18.00 billion.

SunTrust initiated coverage on shares of Citigroup (NYSE: C) with a “buy” rating. Citigroup's stock closed at $37.02 yesterday. Citigroup had $798.78 billion in total cash for the recent quarter.

Analysts at Wedbush initiated coverage on shares of Oracle (NASDAQ: ORCL) with a “neutral” rating. Oracle's shares closed at $32.03 yesterday. Oracle's PEG ratio is 1.00.

Latest Ratings for ALXN

DateFirmActionFromTo
Sep 2014SunTrust Robinson HumphreyInitiates Coverage onBuy
Jul 2014Credit SuisseMaintainsNeutral
Jul 2014JP MorganMaintainsOverweight

View More Analyst Ratings for ALXN
View the Latest Analyst Ratings

Posted-In: Top InitiationsInitiation Analyst Ratings

 

Related Articles (ALXN + C)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters